Literature DB >> 23470007

Restenosis treatments using nanoparticle-based drug delivery systems.

Zi Gu1, Barbara E Rolfe, Anita C Thomas, Zhi Ping Xu.   

Abstract

Restenosis, the re-narrowing of a blood vessel after removal of atherosclerotic plaque, is a major limitation of surgical treatments for atherosclerosis. Various attempts to prevent or treat restenosis by pharmacological or mechanical approaches have had limited success in clinical trials. Hence, there is wide interest in developing new strategies to prevent or treat restenosis. This review discusses 'a new-generation therapy' that uses functional nanoparticles to effectively deliver active drug molecules. The potential platforms for nanoparticle-based solutions to restenosis include organic (e.g. polymers, liposomes, and proteins) and inorganic nanoparticles (e.g. layered double hydroxides, titanium oxide nanotubes, and magnetic nanoparticles,). Many in vitro and in vivo studies based on these platforms demonstrate the feasibility and potential of using nanoparticle drug delivery systems for preventing or treating restenosis, but as yet few have reached clinical trials. It is suggested that using inorganic nanoparticles to target deliver multi-functional drugs will be a promising approach to preventing or treating restenosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23470007     DOI: 10.2174/1381612811319350009

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  2 in total

Review 1.  Iron Oxide Nanoparticles in Regenerative Medicine and Tissue Engineering.

Authors:  Ralf P Friedrich; Iwona Cicha; Christoph Alexiou
Journal:  Nanomaterials (Basel)       Date:  2021-09-08       Impact factor: 5.719

2.  Protein kinase CK2 inhibition suppresses neointima formation via a proline-rich homeodomain-dependent mechanism.

Authors:  K S Wadey; B A Brown; G B Sala-Newby; P-S Jayaraman; K Gaston; S J George
Journal:  Vascul Pharmacol       Date:  2017-09-18       Impact factor: 5.773

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.